亚洲一区二区三区色噜噜,国产成年人精品一区二区,一进一出好大好爽视频,欧美乱妇无乱码,热99在线观看视频

供貨周期	現(xiàn)貨	規(guī)格	T25培養(yǎng)瓶x1 1.5ml凍存管x2
貨號(hào)	BFN60700127	應(yīng)用領(lǐng)域	醫(yī)療衛(wèi)生,生物產(chǎn)業(yè)
主要用途	僅供科研

細(xì)胞名稱	人卵巢腺癌細(xì)胞SK-OV-3
貨物編碼	BFN60700127
產(chǎn)品規(guī)格	T25培養(yǎng)瓶x1	1.5ml凍存管x2
細(xì)胞數(shù)量	1x10^6	1x10^6
保存溫度	37℃	-198℃
運(yùn)輸方式	常溫保溫運(yùn)輸	干冰運(yùn)輸
安全等級(jí)	1
用途限制	僅供科研用途 1類

培養(yǎng)體系	DMEM高糖培養(yǎng)基（Hyclone）+10%胎牛血清（Gibco）+1%雙抗（Hyclone）
培養(yǎng)溫度	37℃	二氧化碳濃度	5%
簡(jiǎn)介	人卵巢腺癌細(xì)胞SK-OV-3由TrempeG和OldLJ在1973年從一位64歲白人女性卵巢腺癌患者的腹腔積液分離得到。該細(xì)胞對(duì)腫瘤壞死因子和幾種細(xì)胞毒性藥物（包括白喉毒素、順鉑和阿霉素）耐受。在裸鼠中成瘤，且形成與卵巢原位癌一致的中度分化的腺癌。該細(xì)胞引種自ATCC HTB-77 。該細(xì)胞在使用過程中，并不被當(dāng)作耐藥細(xì)胞，建議各學(xué)者選用我?guī)炱渌退幖?xì)胞模型。
注釋	Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Part of: JFCR39 cancer cell line panel. Part of: KuDOS 95 cell line panel. Part of: MD Anderson Cell Lines Project. Part of: NCI-60 cancer cell line panel. Part of: OCCP ovarian cancer cell line panel. From: Memorial Sloan Kettering Cancer Center; New York; USA. Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-528. Doubling time: 19 hours (PubMed=2653399); 28 +- 2 hours (PubMed=3804493); 28.8 hours (PubMed=4016745); 75 hours (PubMed=25984343); 48.7 hours (NCI-DTP); ~35 hours (PBCF); 33.29 hours Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger). Omics: Array-based CGH. Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Exosome proteome analysis. Omics: Fluorescence phenotype profiling. Omics: Genome sequenced. Omics: lncRNA expression profiling. Omics: Metabolome analysis. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Misspelling: SCOV-3; Occasionally. Misspelling: SCOV3; Occasionally. Misspelling: SKVO3; Occasionally.
STR信息	Amelogenin X CSF1PO 11 D2S1338 18,23 D3S1358 14 (CCRID; CLS; PubMed=25230021; PubMed=25877200) 13,14 (PubMed=19372543) D5S818 11 D7S820 13,14 D8S1179 14,15 D13S317 8,11 D16S539 12 D18S51 16,17,18 (CCRID; CLS; PubMed=11416159) 16,17 (PubMed=19372543; PubMed=25230021_ECACC_version; PubMed=25877200) 16,18 (PubMed=25230021_academic_lab_version) D19S433 14,14.2 D21S11 30,31,31.2 (CLS; PubMed=11416159; PubMed=30485824) 30,31.2 (CCRID; PubMed=19372543; PubMed=25230021; PubMed=25877200) FGA 24,25 (CCRID; KCLB; PubMed=25230021_academic_lab_version; PubMed=25877200) 24,25,26 (CLS; PubMed=11416159) 23,24,25 (PubMed=25230021_ECACC_version) Penta D 12,13 Penta E 5,13 TH01 9,9.3 TPOX 8,11 vWA 17,18 (AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; ECACC; KCLB; PubMed=11416159; PubMed=25230021_ECACC_version; PubMed=25877200; PubMed=30485824) 18 (PubMed=19372543) 17 (PubMed=25230021_acedemic_version)
參考文獻(xiàn)	Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P., Novak M., Doodnauth S.A., Saiz F.S., Cullis J., Al-Awar R., Neel B.G., McPherson J., Drapkin R., Ailles L., Mes-Massons A.-M., Rottapel R. Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer. Cell Rep. 18:2343-2358(2017) PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096 Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M., Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R., Press M.F., Drapkin R., Easwaran H., Baylin S.B., Slamon D., Velculescu V.E., Scharpf R.B. Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines. Cell Rep. 25:2617-2633(2018) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019) PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019)

驗(yàn)收細(xì)胞注意事項(xiàng)

1、收到人卵巢腺癌細(xì)胞SK-OV-3細(xì)胞，請(qǐng)查看瓶子是否有破裂，培養(yǎng)基是否漏出，是否渾濁，如有請(qǐng)盡快聯(lián)系。

2、收到人卵巢腺癌細(xì)胞SK-OV-3細(xì)胞，如包裝完好，請(qǐng)?jiān)陲@微鏡下觀察細(xì)胞。,由于運(yùn)輸過程中的問題，細(xì)胞培養(yǎng)瓶中的貼壁細(xì)胞有可能從瓶壁中脫落下來，顯微鏡下觀察會(huì)出現(xiàn)細(xì)胞懸浮的情況，出現(xiàn)此狀態(tài)時(shí)，請(qǐng)不要打開細(xì)胞培養(yǎng)瓶，應(yīng)立即將培養(yǎng)瓶置于細(xì)胞培養(yǎng)箱里靜止 3-5 小時(shí)左右，讓細(xì)胞先穩(wěn)定下，再于顯微鏡下觀察，此時(shí)多數(shù)細(xì)胞會(huì)重新貼附于瓶壁。如細(xì)胞仍不能貼壁，請(qǐng)用臺(tái)盼藍(lán)染色法鑒定細(xì)胞活力，如臺(tái)盼藍(lán)染色證實(shí)細(xì)胞活力正常請(qǐng)按懸浮細(xì)胞的方法處理。

3、收到人卵巢腺癌細(xì)胞SK-OV-3細(xì)胞后，請(qǐng)鏡下觀察細(xì)胞，用恰當(dāng)方式處理細(xì)胞。若懸浮的細(xì)胞較多，請(qǐng)離心收集細(xì)胞，接種到一個(gè)新的培養(yǎng)瓶中。棄掉原液，使用新鮮配制的培養(yǎng)基，使用進(jìn)口胎牛血清。剛接到細(xì)胞，若細(xì)胞不多時(shí) 血清濃度可以加到 15％去培養(yǎng)。若細(xì)胞迏到 80%左右，血清濃度還是在 10％。

4、收到人卵巢腺癌細(xì)胞SK-OV-3細(xì)胞時(shí)如無異常情況，請(qǐng)?jiān)陲@微鏡下觀察細(xì)胞密度，如為貼壁細(xì)胞，未超過80%匯合度時(shí)，將培養(yǎng)瓶中培養(yǎng)基吸出，留下 5-10ML 培養(yǎng)基繼續(xù)培養(yǎng)：超過 80%匯合度時(shí)，請(qǐng)按細(xì)胞培養(yǎng)條件傳代培養(yǎng)。如為懸浮細(xì)胞，吸出培養(yǎng)液，1000 轉(zhuǎn)/分鐘離心 3 分鐘，吸出上清，管底細(xì)胞用新鮮培養(yǎng)基懸浮細(xì)胞后移回培養(yǎng)瓶。

5、將培養(yǎng)瓶置于 37℃培養(yǎng)箱中培養(yǎng)，蓋子微微擰松。吸出的培養(yǎng)基可以保存在滅菌過的瓶子里，存放于 4℃冰箱，以備不時(shí)之需。

6、24 小時(shí)后，人卵巢腺癌細(xì)胞SK-OV-3細(xì)胞形態(tài)已恢復(fù)并貼滿瓶壁，即可傳代。（貼壁細(xì)胞）將培養(yǎng)瓶里的培養(yǎng)基倒去，加 3-5ml（以能覆蓋細(xì)胞生長(zhǎng)面為準(zhǔn)）PBS 或 Hanks’液洗滌后棄去。加 0.5-1ml 0.25%含 EDTA 的胰酶消化，消化時(shí)間以具體細(xì)胞為準(zhǔn)，一般 1-3 分鐘，不超過 5 分鐘?？梢苑?/span>入37℃培養(yǎng)箱消化。輕輕晃動(dòng)瓶壁，見細(xì)胞脫落下來，加入 3-5ml 培養(yǎng)基終止消化。用移液管輕輕吹打瓶壁上的細(xì)胞，使之*脫落，然后將溶液吸入離心管內(nèi)離心，1000rpm/5min。棄上清，視細(xì)胞數(shù)量決定分瓶數(shù)，一般一傳二，如細(xì)胞量多可一傳三，有些細(xì)胞不易傳得過稀，有些生長(zhǎng)較快的細(xì)胞則可以多傳幾瓶，以具體細(xì)胞和經(jīng)驗(yàn)為準(zhǔn)。（懸浮細(xì)胞）用移液管輕輕吹打瓶壁，直接將溶液吸入離心管離心即可。